RARE publishes GENGLYCOS 96-week GSDIa trial in Journal of Inherited Metabolic Disease
Ultragenyx (RARE) announced publication of a 96-week randomized, placebo-controlled trial of GENGLYCOS (DTX401) AAV gene therapy in GSDIa with crossover treatment.